Back to Screener

Healthcare

Dyne Therapeutics, Inc.(DYN)

Live Price

Offline

$20.61

+1.38% today

1Y Change

+115.36%

Window

Jun 27, 2025 โ†’ Jun 25, 2026

Market Cap
$2.89B
Revenue Growth
0.0%
EPS Growth
-3.0%
Dividend Yield
0.0%

Coverage: 249 bars ยท Jun 27, 2025 โ†’ Jun 25, 2026

Research Briefing

A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.

Decision context

Research Snapshot

Dyne Therapeutics, Inc. (DYN) is a Healthcare stock with a market cap of $2.89B and listed on NASDAQ. The stock last traded around $20.61 and up 115.4% across the available one-year price window (Jun 27, 2025 โ†’ Jun 25, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of -3.0%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS -3.0%, free cash flow -37.4% with operating margin 0.0% and ROIC -41.0%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines DYN price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.

Benchmark Edge

DYN vs SPY, QQQ, and Sector ETFs

Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.

Shared 1Y chart + MAX history table

Relative Read

Mixed setup vs SPY

DYN is 95.94 pts ahead over the shared 1Y window.

DYN had 30.76 pts deeper max drawdown than SPY.

DYN beat SPY in 2 of 2 calendar years shown and trailed in 0.

DYN

+115.36%

Normalized return

SPY

+19.42%

S&P 500

Excess Return

+95.94 pts

Relative to SPY

DYN Max Drawdown

-39.89%

Trailing 1Y

SPY Max Drawdown

-9.13%

Trailing 1Y

DYNSPY

Calendar-Year Returns

Uses the longest available daily history for DYN and SPY.

YearDYNSPYExcessLeader
2026+11.41%+6.71%+4.70 ptsDYN
2025+100.63%+11.73%+88.90 ptsDYN

Unable to load analyst forecasts.

Timed out loading forecasts for DYN

Next Step

Put consensus data in context

Forecasts are most valuable when they sit beside comparisons, earnings setup, and the rest of the business story.